Aims and scope
A major focus of the journal is on the immunologic processes leading to inflammation, damage and repair as they relate to autoimmune rheumatic and musculoskeletal conditions, and which inform the translation of this knowledge into advances in clinical care.
Original basic, translational and clinical research is considered for publication along with results of early and late phase therapeutic trials, especially as they pertain to the underpinning science that informs clinical observations in interventional studies.
Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
Existing literature on patients with systmetic lupus erythematosus (SLE) suggest that SLE harbors distinct immunophenotypes. Idborg et al investigate how SLE subgroups may differ regarding underlying pathophysiology and characteristic biomarkers.
Their observations indicate underlying pathogenic differences between the SSA/SSB+ and the aPL+ SLE subgroups, suggesting that the SSA/SSB+ subgroup may benefit from IFN-blocking therapies while the aPL+ subgroup is more likely to have an effect from drugs targeting the complement system.
Advertisement
Follow
Annual Journal Metrics
-
Speed
56 days to first decision for reviewed manuscripts only
48 days to first decision for all manuscripts
121 days from submission to acceptance
33 days from acceptance to publicationCitation Impact
4.269 - 2-year Impact Factor
4.668 - 5-year Impact Factor
1.329 - Source Normalized Impact per Paper (SNIP)
2.154 - SCImago Journal Rank (SJR)Usage
1,140 Altmetric Mentions
Advertisement
